SCYNEXIS, Inc. to Present at 10th Annual JMP Securities Life Sciences Conference
RESEARCH TRIANGLE PARK, N.C., June 18, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that David Angulo, M.D., SCYNEXIS' Chief Medical Officer, will present at the 10th Annual JMP Securities Life Sciences Conference at The St. Regis New York in New York City on Wednesday, June 24, 2015, at 11:00 a.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
CONTACT: Media Relations
Heather Savelle
MacDougall Biomedical Communications
Tel: 781-235-3060
hsavelle@macbiocom.com
Investor Relations
Jillian Connell
The Trout Group LLC
Tel: 646.378.2956
jconnell@troutgroup.com
Released June 18, 2015